Abstract
Antibodies that inhibit von Willebrand Factor (VWF)-cleaving protease activity occur in patients with acute thrombotic thrombocytopenic purpura (TTP) and often persist in the chronic phase. A deficiency of this protease is likely to be responsible for the generation of ultrahigh VWF multimers and influence the formation of intra-arterial platelet aggregates that result in microangiopathic haemolytic anaemia, thrombocytopenia and end in organ failure. This report demonstrates complete deficiency of VWF-cleaving protease and the presence of a concentration-dependent IgG1 inhibitor in the plasma of a patient with acquired immunodeficiency syndrome (AIDS). These data may contribute to understanding the pathophysiology of human immunodeficiency syndrome (HIV)-related TTP.
Author supplied keywords
Cite
CITATION STYLE
Sahud, M. A., Claster, S., Liu, L., Ero, M., Harris, K., & Furlan, M. (2002). Von Willebrand factor-cleaving protease inhibitor in a patient with human immunodeficiency syndrome-associated thrombotic thrombocytopenic purpura. British Journal of Haematology, 116(4), 909–911. https://doi.org/10.1046/j.0007-1048.2002.03349.x
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.